CELLINK granted design patent for BIO X

CELLINK is receiving a patent from the U.S. Patent and Trademark Office for the design of the company’s flagship bioprinter.

The patent granted by the U.S. Patent and Trademark Office demonstrates the uniqueness and innovation of CELLINK’s BIO X. BIO X is a standalone bioprinter designed to maximize user-friendliness and functionality.

The new patent protects the product’s unique design and further distinguishes CELLINK from new and existing competitors in the bioprinting field.

“We are extremely pleased to see this patent granted, as protecting our innovative products and technologies is a priority. It strengthens our focus on ensuring that we provide the best long-term value for our customers and shareholders.” - Erik Gatenholm, CEO and co-founder of CELLINK.

BIO X has also been recognized for its design by prestigious awards, including the 2018 Red Dot Award and Stora Designpriset 2019. The patent protects its associated intellectual property and is in line with the company’s strategy in a phase of rapid development of innovative solutions for printing tissues and organs.

For more information, please contact:

Erik Gatenholm, CEO                                                 Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00                                     Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                US +1 (857) 332 2138
Email: [email protected]                                               Email: [email protected]  


CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected].

Latest press releases
March 22, 2020RegulatoryUpdate regarding COVID-19
November 14, 2019Annual Report 2018/2019